Study of a Nebulised Nitric Oxide Generating Solution in Patients With Mycobacterium Abscessus

Summary

* To evaluate the change in M. abscessus cfu/g in induced sputum samples from baseline to the end of treatment with RESP301 in patients with cystic fibrosis who have treatment-naïve or treatment-refractory M. abscessus-pulmonary disease * To assess the safety and tolerability of RESP301 during treatment (28 days) and follow up (84 days) in patients with cystic fibrosis who have treatment naïve or treatment refractory M. abscessus-pulmonary disease

Timeline

Start

2021-11-01

Primary completion

2024-01-31

Completion

2024-04-23

Drugs

Indications